Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adjuvance, Amivas, Clearb, Emergex, Gylden, Jaguar Health, Kezar Life, Kiji, Napo, Oncozenge, Pharmanovia, Regimmune, Zosano.

The top 10 biopharma stock gainers and losers for the week.

A quick look back at top stories.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amylyx, Anavex, Aura, Biodexa, Curevo, George Medicines, Innovent, Kezar, Merck, Nektar, Neuvivo, Supernus, Theratechnologies.

Biopharmas raising money in public or private financings, including: Bright Minds, Treeline.

New hires and promotions in the biopharma industry, including: Aavantgarde, Pacira, Vianautis.

Astellas Pharma Inc. gained U.S. FDA approval of first-in-class claudin 18.2-targeted treatment Vyloy (zolbetuximab-clzb), now indicated as a first-line therapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.

Year-to-date money raised in public, private and other financings of biopharma companies.

The U.S. SEC filed insider trading charges against Ruimin Xie, the former director of analytical development at Bellus Health Inc., for allegedly receiving ill-gotten gains of $59,408.42 by acting on word of a potential acquisition by GSK plc.